SCHEMBL16016404

SCHEMBL16016404

Cc1ncc(Cc2cccc(Cl)c2F)[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
MPO P05164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.36
AKR1B1 P15121 1/20 0.36
BRS3 P32247 2/20 0.35
P2RX7 Q99572 1/20 0.34
FDPS P14324 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TGFBR1 P36897 1/20 0.33
GUCY1B2 O75343 1/20 0.33
GUCY1A2 P33402 1/20 0.33
GUCY1A1 Q02108 1/20 0.33
GUCY1B1 Q02153 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
CD38 P28907 1/20 0.32
RXRA P19793 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16020968 0.77 MPO (0.39) MPOSMN1; SMN2AKR1B1P2RX7TAAR1
SCHEMBL16020970 0.77 MPO (0.40) MPOSMN1; SMN2AKR1B1P2RX7CYP3A4
SCHEMBL16016418 0.76 MPO (0.41) MPOSMN1; SMN2AKR1B1P2RX7CYP3A4
SCHEMBL16016415 0.74 MPO (0.39) MPOAKR1B1P2RX7TAAR1ADORA2A
SCHEMBL2708549 0.73 HRH4 (0.67) HRH1HRH4SMN1; SMN2FDPSADORA2B
SCHEMBL2744736 0.73 ADRA1D (0.55) HRH4SMN1; SMN2CYP3A4TAAR1
SCHEMBL16016407 0.72 MPO (0.38) MPOAKR1B1P2RX7TAAR1CD38
SCHEMBL16016408 0.71 MPO (0.42) MPOSMN1; SMN2AKR1B1P2RX7CD38
SCHEMBL16016398 0.71 KMT2A (0.45) MPOSMN1; SMN2P2RX7GRM4LMNA
SCHEMBL16020965 0.71 MPO (0.37) MPOSMN1; SMN2AKR1B1P2RX7CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2774928-B1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY SHIONOGI & CO (JP) 2017-08-30 EP disclosed
US-9200009-B2 Polycyclic pyridone derivative having integrase inhibitory activity SHIONOGI & CO., LTD. (JP) 2015-12-01 US disclosed
US-20140256937-A1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-2774928-A1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2014-09-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256937-A1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY TYMP, CDK6, IMPA1 HRH1 3117/4885HRH4 3784/4885MPO 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.